Literature DB >> 1323290

A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor.

N Gotoh1, A Tojo, M Hino, Y Yazaki, M Shibuya.   

Abstract

Epidermal growth factor receptor (EGF-R) is a widely expressed ligand-dependent tyrosine kinase. The tyrosine residue at 845 in EGF-R corresponds to Y416 of v/c-src kinase, which is highly conserved and functionally important in many tyrosine kinases. To clarify the functional role of Y845, we constructed a mutant human EGF-R in which this tyrosine was replaced with phenylalanine and transfected it to NIH3T3 cells. EGF-R F845 induced EGF-dependent cellular transformation and revealed tyrosine-autophosphorylation of a 170 kDa protein, and initiated DNA synthesis similar to the wild-type EGF-R. We conclude here that Y845 is dispensable in the above mentioned functions of EGF-R tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323290     DOI: 10.1016/0006-291x(92)90812-y

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations.

Authors:  Yingting Liu; Jeremy Purvis; Andrew Shih; Joshua Weinstein; Neeraj Agrawal; Ravi Radhakrishnan
Journal:  Ann Biomed Eng       Date:  2007-02-02       Impact factor: 3.934

2.  Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase.

Authors:  Hao Zhang; Wei Shen; Don Rempel; John Monsey; Ilan Vidavsky; Michael L Gross; Ron Bose
Journal:  Mol Cell Proteomics       Date:  2011-03-21       Impact factor: 5.911

3.  HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Authors:  Delphine R Boulbes; Stefan T Arold; Gaurav B Chauhan; Korina V Blachno; Nanfu Deng; Wei-Chao Chang; Quanri Jin; Tzu-Hsuan Huang; Jung-Mao Hsu; Samuel W Brady; Chandra Bartholomeusz; John E Ladbury; Steve Stone; Dihua Yu; Mien-Chie Hung; Francisco J Esteva
Journal:  Mol Oncol       Date:  2014-11-11       Impact factor: 6.603

4.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism.

Authors:  G Pines; P H Huang; Y Zwang; F M White; Y Yarden
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

5.  Dissecting the roles of tyrosines 490 and 785 of TrkA protein in the induction of downstream protein phosphorylation using chimeric receptors.

Authors:  Jordane Biarc; Robert J Chalkley; A L Burlingame; Ralph A Bradshaw
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

6.  An investigation of the role of Glu-842, Glu-844 and His-846 in the function of the cytoplasmic domain of the epidermal growth factor receptor.

Authors:  J F Timms; M E Noble; M Gregoriou
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

7.  In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.

Authors:  Chen Qiu; Mary K Tarrant; Tatiana Boronina; Patti A Longo; Jennifer M Kavran; Robert N Cole; Philip A Cole; Daniel J Leahy
Journal:  Biochemistry       Date:  2009-07-21       Impact factor: 3.162

8.  Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity.

Authors:  N Gotoh; A Tojo; K Muroya; Y Hashimoto; S Hattori; S Nakamura; T Takenawa; Y Yazaki; M Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

9.  EGFR: tale of the C-terminal tail.

Authors:  Ketan S Gajiwala
Journal:  Protein Sci       Date:  2013-06-11       Impact factor: 6.725

10.  Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.

Authors:  John F Flynn; Christina Wong; Joseph M Wu
Journal:  J Oncol       Date:  2009-04-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.